1 / 9

Infectious Vaccines Partnering Terms and Agreements

Bharat Book Presents The present report on "Infectious Vaccines Partnering Terms and Agreements

bharatbookseo
Download Presentation

Infectious Vaccines Partnering Terms and Agreements

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infectious Vaccines Partnering Terms and Agreements One-Stop Shop for Business Information

  2. Summary The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

  3. This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

  4. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company?What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How aresalesand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture?

  5. How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

  6. Table of Contents Executive SummaryChapter 1 – IntroductionChapter 2 – Trends in infectives vaccine dealmaking2.1. Introduction2.2. Infectious Vaccines partnering over the years2.3. Bigpharma Infectious Vaccines dealmaking activity2.4. Most active in Infectious Vaccines partnering2.5. Infectious Vaccines partnering by deal type2.6. Infectious Vaccines partnering by stage of development2.7. Infectious Vaccines partnering by infectives indication2.8. Infectious Vaccines partnering by vaccine and adjuvant indication2.9. Disclosed deal terms for Infectious Vaccines partnering

  7. Related Reports • World Vaccines Market 2013-2023 • Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives) • Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 • NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

  8. Custom Research Incase the reports don’t match your requirement then we can do a Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us at a unique position to take up Custom Research demands of yours. We provide the specifications of the custom research job to a dedicated team comprising of researchers, analysts and industry experts, who have close experience and understanding of global markets, competitive landscapes, various business models, market shares, drivers, restraints and benchmarks. http://www.bharatbook.com/customResearch.asp

  9. For More Information You Can Visit: http://www.bharatbook.com/healthcare-market-research-reports/infectious-vaccines-partnering-terms-and-agreements.html Request Sample Pages Contact Us:-Call India: +91-22-27810772/73 Call USA/Canada (Toll Free): 1-866-279-8368 For Live Chat - http://bit.ly/19m3TU4 Follow/Like Us on:-

More Related